| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
|
Lancia, Carlo
|
|
2019
|
83 |
5 |
p. 951-962
|
artikel
|
| 2 |
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial
|
Nishikawa, Kazuhiro
|
|
2019
|
83 |
5 |
p. 867-874
|
artikel
|
| 3 |
CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy
|
Liu, Duo
|
|
2019
|
83 |
5 |
p. 939-949
|
artikel
|
| 4 |
Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia
|
Naushad, Shaik Mohammad
|
|
2019
|
83 |
5 |
p. 875-880
|
artikel
|
| 5 |
Determination of melphalan in human plasma by UPLC–UV method
|
Huang, Liusheng
|
|
2019
|
83 |
5 |
p. 905-910
|
artikel
|
| 6 |
Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer
|
Zhang, Wei
|
|
2019
|
83 |
5 |
p. 911-920
|
artikel
|
| 7 |
Eligibility criteria for phase I clinical trials: tight vs loose?
|
Malik, Laeeq
|
|
2019
|
83 |
5 |
p. 999-1002
|
artikel
|
| 8 |
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer
|
Kawata, Toshio
|
|
2019
|
83 |
5 |
p. 849-858
|
artikel
|
| 9 |
Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model
|
Thorpe, Daniel
|
|
2019
|
83 |
5 |
p. 893-904
|
artikel
|
| 10 |
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
|
Iwase, Mariko
|
|
2019
|
83 |
5 |
p. 993-998
|
artikel
|
| 11 |
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects
|
Prakash, Chandra
|
|
2019
|
83 |
5 |
p. 837-848
|
artikel
|
| 12 |
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
|
Yuan, Peng
|
|
2019
|
83 |
5 |
p. 963-974
|
artikel
|
| 13 |
Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay
|
Sanchez, Lydia
|
|
2019
|
83 |
5 |
p. 827-835
|
artikel
|
| 14 |
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
|
Yamaguchi, Ou
|
|
|
83 |
5 |
p. 817-825
|
artikel
|
| 15 |
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
|
Yamaguchi, Ou
|
|
2019
|
83 |
5 |
p. 817-825
|
artikel
|
| 16 |
Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model
|
Miyake, Kentaro
|
|
2019
|
83 |
5 |
p. 809-815
|
artikel
|
| 17 |
Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report
|
Couty, Emmanuelle
|
|
2019
|
83 |
5 |
p. 881-892
|
artikel
|
| 18 |
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS
|
Cohen, Ian Joseph
|
|
2019
|
83 |
5 |
p. 859-866
|
artikel
|
| 19 |
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
|
Melisi, Davide
|
|
2019
|
83 |
5 |
p. 975-991
|
artikel
|
| 20 |
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma
|
Albin, Nicolas
|
|
2019
|
83 |
5 |
p. 1003-1005
|
artikel
|
| 21 |
The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men
|
Shiota, Masaki
|
|
2019
|
83 |
5 |
p. 933-938
|
artikel
|
| 22 |
The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
|
Chen, Liangfeng
|
|
2019
|
83 |
5 |
p. 921-931
|
artikel
|
Tijdschrift beschrijving